7 recruiting, 5 active not recruiting, 2 not yet recruiting, 2 terminated. 12 Phase 2, 4 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Replimune, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma | Phase 2 | Not yet recruiting | Yana Najjar | 34 | 2026-12-31 | 2026-10-07 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma Vusolimogene Oderparepvec (VO), Pembrolizumab - Angiosarcoma, Angiosarcoma, Adult | Phase 2 | Recruiting | Varun Monga, MBBS | 18 | 2026-01-09 | 2026-09-01 |
| A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 Observational study with no interventions - Melanoma, Metastatic Melanoma | Recruiting | Replimune, Inc. | 50 | 2025-12-12 | 2026-01-12 | |
| Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease RP2 Injection - High-Risk Oral Precancerous Disease | Phase 2 | Recruiting | Glenn J. Hanna | 25 | 2025-01-01 | 2026-04-23 |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma RP2, Ipilimumab, Nivolumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Recruiting | Replimune, Inc. | 280 | 2024-12-17 | 2026-04-02 |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC RP2, Bevacizumab, Atezolizumab - Hepatocellular Carcinoma, Biliary Tract Cancer | Phase 2 | Recruiting | Replimune, Inc. | 60 | 2024-08-01 | 2026-04-02 |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Replimune, Inc. | 400 | 2024-07-11 | 2026-07-15 |
| "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer Atezolizumab + RP1 - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Terminated | Institut Curie | 2 | 2024-04-05 | 2025-06-11 |
| RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Vusolimogene oderparepvec (RP1) - Melanoma | Early Phase 1 | Recruiting | Yana Najjar | 25 | 2024-03-07 | 2026-04-13 |
| Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel - Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Replimune, Inc. | 2024-01-30 | 2025-03-11 | |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Terminated | Replimune, Inc. | 5 | 2023-06-29 | 2026-02-02 |
| Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours RP3, Nivolumab - Advanced Solid Tumor | Phase 1 | Active not recruiting | Replimune, Inc. | 123 | 2020-12-29 | 2026-02-27 |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies RP1, intra-tumoral injection, oncolytic virus - Merkel Cell Carcinoma, Basal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Replimune, Inc. | 69 | 2020-05-15 | 2026-04-22 |
| Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors RP2, nivolumab - Cancer | Phase 1 | Active not recruiting | Replimune, Inc. | 36 | 2019-10-17 | 2026-02-27 |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Cemiplimab, RP1 - Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Replimune, Inc. | 231 | 2019-10-08 | 2025-01-27 |
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) RP1, nivolumab - Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H) | Phase 2 | Active not recruiting | Replimune, Inc. | 340 | 2017-09-20 | 2026-02-13 |
| An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma RP1, Nivolumab - Advanced Melanoma | No longer available | Replimune, Inc. | 2025-12-18 |
Melanoma (6) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Neoplasms (2) · Uveal Melanoma (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Hemangiosarcoma (1)
Nivolumab (8) · MAPRE1 protein, human (3) · atezolizumab (3) · Bevacizumab (2) · pembrolizumab (2) · Carboplatin (1) · Docetaxel (1) · Filgrastim (1) · Fluorouracil (1) · Ipilimumab (1) · Leucovorin (1) · Observation (1) · Opdualag (1) · Oxaliplatin (1) · Paclitaxel (1)
United States (15) · France (6) · Spain (6) · United Kingdom (6) · Germany (4) · Greece (4) · Australia (3) · Poland (3) · Bulgaria (1) · Canada (1) · Czechia (1) · Italy (1)
Gary Vanasse, MD (4) · Jeannie Hou, MD (4) · David Cohan, MD/FACS (1) · Glenn Hanna, MD (1) · Moran Mishal, MD (1) · Rahul Marpadga, MD MPH (1) · Steven Le Gouill, PhD (1) · Tom Hash, MD (1) · Varun Monga, MBBS (1) · William Chapin, MD, MSCE (1) · Yana Najjar, MD (1)
2016 (1)